Dofetilide
Dofetilide, sold as Tikosyn, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug with Vaughan Williams Class III activity; it blocks a potassium current in the heart. The label read lists two uses: the maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than a week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It says the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal. The label carries a boxed warning about induced arrhythmia.
Also called Tikosyn
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 49247 (dofetilide, no salt); UNII R4Z9X1N2ND (exact). MeSH has no descriptor for dofetilide (the exact-label descriptor lookup returned an empty list); the term dofetilide exists (T205355) but is not a descriptor, so no MeSH code was added. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic [EPC]). The label read is the Pfizer Laboratories Div Pfizer Inc label for Tikosyn capsules, application NDA020931, effective 2026-04-21 in openFDA. Drugs@FDA also lists a generic product (ANDA210740) whose brand name is a misspelling of dofetilide; generic labels were not read. This page records label indications, the class, the mechanism sentence and the boxed warning only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says dofetilide shows Vaughan Williams Class III antiarrhythmic activity by blocking the cardiac ion channel that carries the rapid component of the delayed rectifier potassium current.
Claims and evidence
Context Patients starting or restarting Tikosyn, as described in a US label boxed warning
- Recipient
- Recipient not specified
- Population
- Patients who are started or restarted on the medicine, as the boxed warning describes them. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients initiated or re-initiated on Tikosyn
- Excluded
- None stated
The same US label carries a boxed warning about the risk of induced arrhythmia in patients who start or restart the medicine. The warning also names the setting in which treatment is to begin; that instruction is not repeated here.
Applies to Recipient not specified Patients starting or restarting Tikosyn, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the subject of the label's boxed warning only. The warning goes on to say what prescribers must do when treatment starts or restarts, and the label gives dosing instructions; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].boxed_warning[0], first sentence
- How it applies
- Label passage quoted in the research quote table (LB-11).
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260421.
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm
- Patients with atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought
- Excluded
- None stated
The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.
Applies to Recipient not specified Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].description[0], first sentence
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], maintenance of normal sinus rhythm
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06).
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], conversion
- How it applies
- Label passage quoted in the research quote table (LB-07, LB-08).
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260421.
- Retrieved
- Source effective date
- 2026-04-21
- Source state
- Current
- Version fingerprint
97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn
The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication: Atrial flutter
Applies to Recipient not specified Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn
The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:dofetilide- Content hash
717bd69ce8d1e9aa56bb79bc9b5545c4a66467ef33fa76fabceed15d4abd5ebf